Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Cognitive Dysfunction × Exercise × Clear all

Phase

Phase NA 4 Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Motor Activity 9 Neoplasms 5 Breast Neoplasms 5 Prostatic Neoplasms 2 Patient Compliance 2 Leukemia, Myeloid, Acute 2 Fatigue 2 Brain Neoplasms 2 Weight Loss 1 Weight Gain 1 Smoking Cessation 1 Peripheral Nervous System Diseases 1 Overweight 1 Ovarian Neoplasms 1 Obesity 1 Neuroectodermal Tumors, Primitive 1 Neoplasm Metastasis 1 Medulloblastoma 1 Lung Neoplasms 1 Infratentorial Neoplasms 1 Fallopian Tube Neoplasms 1 Colorectal Neoplasms 1 Cognitive Dysfunction 1 Carcinoma, Hepatocellular 1 Bone Metabolism Biomarkers 1

Interventions

Memantine 2 lithium sulfate 1 lime 1 XENP 1595 1 Ramipril 1 Methylphenidate 1 Lithium 1 Infliximab 1 Ibuprofen 1 Exercise 1 Cannabidiol 1 Behavior Therapy 1 Aspirin 1 Ashwagandha 1 Anticonvulsants 1 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00495703 2017-04-04

TACTIC

Vanderbilt University Medical Center

Phase 2 Completed

Motor Activity, Neoplasms, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon ⚡